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Abstract
Summary: The main objective was to evaluate the association between SNPs and haplotypes of the FABP1-4 genes and type
2 diabetes, as well as its interaction with fat intake, in one general Spanish population. The association was replicated in a
second population in which HOMA index was also evaluated.
Methods: 1217 unrelated individuals were selected from a population-based study [Hortega study: 605 women; mean age
54 y; 7.8% with type 2 diabetes]. The replication population included 805 subjects from Segovia, a neighboring region of
Spain (446 females; mean age 52 y; 10.3% with type 2 diabetes). DM2 mellitus was defined in a similar way in both studies.
Fifteen SNPs previously associated with metabolic traits or with potential influence in the gene expression within the FABP1-
4 genes were genotyped with SNPlex and tested. Age, sex and BMI were used as covariates in the logistic regression model.
Results: One polymorphism (rs2197076) and two haplotypes of the FABP-1 showed a strong association with the risk of DM2
in the original population. This association was further confirmed in the second population as well as in the pooled sample.
None of the other analyzed variants in FABP2, FABP3 and FABP4 genes were associated. There was not a formal interaction
between rs2197076 and fat intake. A significant association between the rs2197076 and the haplotypes of the FABP1 and
HOMA-IR was also present in the replication population.
Conclusions: The study supports the role of common variants of the FABP-1 gene in the development of type 2 diabetes in
Caucasians.
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Introduction
Type 2 diabetes (DM2), obesity and abdominal fat distribution
are cardiometabolic risk factors that cluster frequently. In their
origin, fetal, environmental and genetic factors may play a role.
The genetic susceptibility follows a complex trait inheritance,
where the interaction between multiple genes and environmental
factors results in the final phenotype. Among the candidate genes,
the fatty acid binding protein gene family (FABPs) has been studied
due to its role in the uptake, intracellular metabolism and
excretion of long chain fatty acids (LCFA) [1]. Several authors
linked polymorphisms of these genes with different metabolic
phenotypes. Two missense mutations, the c.163 A.G (p.Ala54Thr)
polymorphism of the intestinal FABP (FABP2) [2,3,4,5], the c.280
A.G (p.Thr94Ala) of the liver FABP (FABP1) [6,7] and one
polymorphism in the promoter region of the adipose FABP
(FABP4) [8] were frequently related with metabolic abnormalities
including DM2. In addition, SNPs of the muscular FABP (FABP3)
have been linked to DM2 in an Asian population [9].
Furthermore, polymorphisms of this gene family have also been
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linked to cardiovascular risk and coronary heart disease [10]. The
potential interaction of these genes with fat dietary content has not
been clearly elucidated but for a few papers [5].
The purpose of the present study was to evaluate the association
between specific SNPs and haplotypes of the FABP1-4 genes and
DM2, obesity and abdominal obesity in two independent
populations. Besides, we evaluated the potential interaction of
these genetic variants with total, saturated and polyunsaturated fat
intake as well as the genetic association with Homeostasis
Assessment Index (HOMA-IR) in the replication population.
Methods
Study populations
The association analysis was first made in one thousand two
hundred and seventeen subjects with high genotyping call rate,
selected from a large epidemiologic study which was carried out in
the Rio Hortega Hospital of Valladolid [11,12,13] (Hortega
population). Population selection and methodology have been
previously described [12]. In summary, the sample included
individuals older than 18 years in the absence of serious
concomitant disease or psychiatric disorder, which could interfere
with the study. To be representative of the general population,
investigators calculated the sample size by using local public
resources and finally 1502 subjects were included. For replication,
we selected eight hundred and five subjects from another
population-based epidemiological study, in Segovia, which is also
located in a central region of Spain. This study also included a
large number of subjects but in the same way as we did with
Hortega, those subjects with low genotyping call rate were not
included. Description of the sampling methodology and charac-
teristics of this study were previously published [14,15].
All the subjects included in the study were Caucasians living in
an area with low immigration rate. The local Ethical Committees
of the following hospitals: Rio Hortega Hospital from Valladolid
and San Carlos Clinical Hospital from Madrid approved the
Hortega and the Segovia-VIVA studies respectively and all the
participants gave written agreement to participate. Additionally
the participants gave their informed consent to use their blood
samples for genetic studies.
Assessment of cardiometabolic risk factors
The two studies included the determination, among others, of
anthropometric measurements, blood pressure, glycaemia, lipid
profile and smoking status as well as personal and familial
information about cardiovascular risk factors.
Body mass index (BMI) was calculated using the following
formula ‘‘weight (kg)/height (m2)’’; Weight was assessed with
precise scales while the individuals were without shoes and with
light clothing. Height was determined in a similar way. A subject
was classified as obese if his/her BMI was $30 Kg/m2. Waist
circumference was measured according to standard recommen-
dations. Patients were classified to have central obesity when their
waist was .102 and .88 cm for men and women, respectively
according to the ATP-III criteria [16].
Assessment of glucose and lipid profile differed in the two study
populations. In the Hortega, blood samples were obtained with a
mean of 3 hours fasting (range 0–17). Basic serum biochemistry
and lipid profile (total cholesterol, HDL cholesterol and triglyc-
erides) were measured with an Hitachi 917 autoanalyzer
(Boehringer, Germany). Glucose was measured by the glucose
oxidase method and LDL cholesterol was calculated using the
Friedewald formula. In Segovia population, blood samples were
obtained after 10 hours fasting. Glucose was measured twice by
the glucose oxidase method with an autoanalyzer (Hitachi 704,
Boehringer Mannheim, Germany). Total cholesterol, triglycerides
and HDLc were assessed with an enzymatic method by means of
standard analyzers (Boehringer Mannheim, Germany). LDL
cholesterol was calculated with the Friedewald formula.
The definition of type 2 diabetes was slightly different in both
studies. In Hortega subjects were considered as diabetics if they
were already diagnosed of type 2 diabetes by a physician or if the
plasma glucose remained equal or higher than 126 mg/dl after the
extraction of a second sample in fasting conditions in those
subjects with glucose equal or higher than 140 mg/dl in non
fasting conditions [11]. By contrast, in Segovia, individuals with
fasting glucose equal to or higher than 126 mg/dl, already
diagnosed or having antidiabetic treatment were classified as
diabetics. In this last population an oral glucose tolerance test was
performed and interpreted according to the recommendations of
the expert panel for the diagnosis and classification of DM2 [17].
Moreover, in the Segovia population, HOMA-IR index was
calculated: fasting insulin (mU/ml) 6 fasting glucose (mmol/l)/
22.5. This information was not available in Hortega because the
main objective of this study was to estimate the prevalence of the
main cardiovascular risk factors at a population level whereas the
aim of the Segovia study was to investigate the prevalence of
anthropometrics and physiological parameters related to obesity
and others components of the metabolic syndrome.
Nutrient Intake Assessment
Diet was assessed within the Hortega study by a validated
questionnaire, which used two 24-hour recalls and one semi
quantitative survey. The nutrient composition was determined
with the food composition tables of the nutritional department of
the University of Granada and the data were analyzed with the
statistical program ‘‘BitASDE’’ and with the license of the Medical
School. Total, saturated and polyunsaturated fat intakes were
estimated in g/day and their potential interaction with variants of
the FABP genes was considered.
Genotyping
DNA was isolated from peripheral blood cells using Chemagic
System (Chemagen) and samples were diluted to a final
concentration of 100 ng/ml. The DNA samples used in this
project were related to the Clinical Hospital Biobank of Valencia.
The genotyping was assessed using an oligo-ligation assay,
SNPlex (Applied Biosystems, Foster City, CA). Fifteen SNPs of the
FABP1-4 genes were selected. We included variants with potential
influence in the gene and protein function as well as the most
important variants described in the literature. Reference names
and characteristics of the selected single nucleotide polymorphisms
(SNPs) are shown in Table 1.
Genotypes were obtained with the software GeneMapper v4.0
(Applied Biosystems, Foster City, CA). Allelic and genotypic
frequencies were determined for every SNP.
We used the following filters in this study: 90% as the lowest call
rate for individuals and SNPs, 1% as the lowest minor allele
frequency for SNPs and 0.001 as p-value for Hardy-Weinberg
equilibrium.
Statistical analysis
All values were expressed as mean 6 standard deviation.
ANOVA test was used to compare quantitative variables between
groups and chi-square test for categorical variables using the
statistical software StataIC 11 (StataCorp4905 Lakeway drive
,College Station, Texas, 77845, USA).
FABP Genes and Type 2 Diabetes
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Genetic association analysis with type 2 diabetes, obesity
(based on the BMI values) and abdominal obesity (based on the
waist circumference values) were sought by logistic regression
models adjusted for age and sex in the case of obesity and also
for BMI in the case of abdominal obesity and type 2 diabetes.
The interaction with fat intake was assessed by including a
multiplicative term within the adjusted logistic regression
models. Total, saturated, monounsaturated and polyunsatu-
rated fat intakes were included in the model as quantitative
traits but also as qualitative traits based on quartiles and
tertiles of the continuous variable. Logistic and linear
regression models adjusted by age, sex and BMI were used
to evaluate the association of the selected SNPs with insulin
resistance expressed as a dichotomous trait or as a continuous
trait in Segovia population. The cut-off to consider insulin
resistance was 3.8 in agreement with the recommendations of
Ascaso et al(18) for Spanish populations. This association was
performed with or without including those subjects with type 2
diabetes.
Linkage disequilibrium (LD) was estimated by R-square and
haplotype frequencies by the Expectation Maximization Algo-
rithm (EM) [18]. Haplotype association was analyzed by logistic
regression adjusted by the same covariables as the individual SNP
analysis and using the sliding window approach up to six markers
and a proxy approach taking into account the results of the
individual SNP association. Tag-SNPs, LD and haploblocks were
calculated using Haploview version 3.32 [19].
We used the free software Quanto v1.2.4 [20,21] to calculate
the statistical power with the qualitative traits under additive and
dominant models taking into account the minor allele frequency of
the selected SNPs, the final sample size, the prevalence of the
metabolic traits in our sample and different genotypes relative risk.
For the majority of the variants we had more than 80% of power
to detect associations with an effect size of 1.8 or higher and with a
type I error of 0.05. The individual SNP and haplotype analysis
was performed with the program PLINK v.1.06 developed by
Purcell (http://pngu.mgh.harvard.edu/purcell/plink/). To deal
with the multiple comparisons problem we used the Bonferroni p-
value to consider a result as significant.
Results
Although the genotyping procedure was performed in 1502
subjects from the Hortega study and 1241 subjects from the
Segovia study, after excluding those subjects with call rate
lower than 90% (285 subjects in Hortega and 436 in Segovia),
the final sample sizes were 1217 in Hortega and 805 in
Segovia. The genotyping call rate for the remaining individuals
was 98.8 in Hortega and 98.6% in Segovia. The individuals
from the latter population were younger (52 y vs 54 y), had
higher BMI, total cholesterol, and lower levels of triglycerides
and systolic blood pressure than individuals from the Hortega
study had. The prevalence of DM2, obesity and abdominal
obesity was higher in Segovia than in Hortega population.
Only 84 (6.9%) out of 1217 subjects in Hortega were under
hypolipemiant treatment. In Segovia, this information was
missing in a great proportion of patients. From the 210 patients
in whom the information about the lipid lowering treatment
was available, 54 (25.7%) were under hypolipemiant treat-
ment. The main characteristics of the selected individuals from
both populations are shown in Table 2.
In Hortega population the SNP, rs1799883, within the FABP2
gene was excluded because of low genotyping call rate. The
other fourteen SNPs passed the pre-defined thresholds and the
call rate for the remaining SNPs was 98.8%. In Segovia
population, two SNPs (rs2970901 of FABP1 and rs2279885 of
FABP3) were excluded because of low genotyping call rate or
MAF lower than 1%. The other thirteen SNPs passed the pre-
defined thresholds and the call rate for the remaining SNPs was
98.6%. In the pooled analysis, three SNPs (rs4834770 and
rs1799883 on FABP2 and rs2279885 on FABP3) were excluded.
The other twelve SNPs passed the pre-defined thresholds and
Table 1. Information of the selected polymorphisms for each FABP gene.
Locus Gene Name HGN SNP1 CHR position Reference2 Consequence
2p11 Fatty acid-binding protein, liver FABP1 rs2197076* 88203873 c.334-135 G.A 3 prime UTR
rs2241883* 88205181 c.280 A.G (p.T94A) Non synonymous coding
rs2970901* 88209949 c.-1238 G.T Upstream
4q28-q31 Fatty acid binding protein 2, intestinal FABP2 rs1511025 120459686 c.357 A.G (p.V119V) Synonymous coding
rs4834770 120461297 c. 216 T.C (p.N72N) Synonymous coding
rs1799883 120461344 c.163 A.G (p.A54T) Non synonymous coding
rs6857641 120462959 c.-254 T.C 5 prime UTR
rs2282688 120463170 c.-465 A.G Upstream
rs10034579 120463477 c.-772 A.C Upstream
1p33-p32 Fatty acid binding protein 3, muscle and heart FABP3 rs2271072 31613013 c.247-85 C.G Intronic
2345CT 31618855 c.-345 C.T Promoter
rs12401792* 31620006 c. -1559 G.T Within non coding gene
8q21 Fatty acid binding protein 4, adipocyte FABP4 rs8192688* 82555404 c.74-16 C.T Intronic
rs16909225 82558914 c.-957 A.G Upstream
rs2279885 31845686 c.73+103G.C Intronic
1, dbSNP 126.
2, It begins in the first nucleotide of exon 1, Build 126, Ensembl release 41.
HGN: The HUGO Gene Nomenclature.
*Tag-SNP by Hapmap in caucasic subjects.
doi:10.1371/journal.pone.0031853.t001
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the call rate for the remaining SNPs was 98.5%. The SNP call
rates for each population and for the pooled sample after
exclusion of subjects and SNPs with low genotyping call rate are
shown in Table S1.
Individual SNPs association with type 2 diabetes, obesity
and abdominal obesity
One polymorphism of the FABP1 gene was strongly associated
with the risk of type 2 diabetes in Hortega population even when
Bonferroni test was applied for multiple comparisons. The allele A
of the rs2197076 increases the risk of having DM2 under additive
but especially under dominant model [OR 2.15 (1.36–3.40) p-
value 0.001004; Bonferroni p-value 0.0140]. This result was
further confirmed in Segovia population [OR 2.05 (1.25–3.36) for
the dominant model, p-value 0.0041; Bonferroni p-value 0.053]
and in the pooled analysis [OR 2.10 (1.50–2.92) for the dominant
model, p-value 1.31E-05; Bonferroni p-value 0.00015].
The association among variants of the other FABP genes and
the other metabolic traits, obesity and abdominal obesity, was
quite inconclusive (Tables S2 and S3). The individual SNP
association analyses for the additive, dominant and recessive
models are shown in Table 3.
The total counts and frequencies of the different alleles and
genotypes of the selected SNPs according to the diabetes state in
each population have been summarized in Table S4.
Haplotype association analysis with type 2 diabetes,
obesity and abdominal obesity
One haplotype including the allele A of the rs2197076 and the
allele T of the rs2241883 (p.Thr94Ala) significantly increased the
risk of having type 2 diabetes in Hortega, Segovia and in the
pooled analysis [OR 1.81 in Hortega, p-value 0.0039; OR 1.76 in
Segovia, p-value 0.00692; OR 1.79 in the pooled analysis, p-value
7.5E-05]. Another haplotype including the G allele of the
rs2197076 resulted in protection against type 2 diabetes, the
results being highly significant in Segovia and in the pooled
analysis. The proxy approach also found significant association
with both the individual marker and the haplotype, which
reinforces the results. Figure 1 shows the LD of that region of
chromosome 2 with the two markers (R-sq,0.8).
SNP and haplotype association with HOMA-IR
We evaluated the possible association of polymorphisms of the
FABP-1 gene with insulin resistance in the replication population.
There was a significant association between genotypes of the
rs2197076 polymorphism and HOMA-IR values expressed as a
quantitative trait in the dominant model. Carriers of the allele A of
this SNP had HOMA-IR values around 0.60 units higher than
homozygotes GG. The results were significant even when the
Bonferroni correction was applied but this association weakened
after exclusion of diabetics subjects under treatment and
Table 2. General characteristics of the studied subjects.
Characteristic Pooled population Hortega Segovia-Viva
No. of Subjects 2022 1217 805
Age (y) 54616.6 54.8619.3 52.8611.2**
Sex (Male/female) 971/1051 612/605 359/446*
Body Mass Index (kg/m2) 26.864.2 26.464.2 27.564.1***
Waist Perimeter (cm) 91.1612.3 89.4 612.9 93.7610.8***
Obesity (n, %) 408 (20.7) 206 (17.6) 202(25.2)***
Abdominal Obesity (n, %) 720 (36.5) 357 (30.4) 363 (45.4)***
Diabetes Mellitus (n, %) 174 (8.9) 95 (7.8) 79 (10.34)0.052
Plasma Glucose (mg/dL) 91.6619.6 92.1619.4 90.9619.8
HOMA INDEX NA NA 2.9762.6
Hypertension (n, %) 851(42.3) 510 (41.9) 341 (43.0)
Systolic Blood Pressure (mmHg) 128.4620.3 130.7621.3 124.8618.1***
Diastolic Blood Pressure (mmHg) 78.9610.4 79.3610.6 78.3610.1*
Total Cholesterol (mg/dL) 206.6639.1 201.0638.3 215.7638.7***
HDL-Cholesterol (mg/dL) 54.1615.7 51.8614.1 57.7617.3***
Triglycerides (mg/dL) 147.76104.8 175.56109.9 103.2677.7***
Lipid lowering treatment (n, %) 138 (9.6)1 84 (6.9) 54 (25.7)2
Total fat intake: NA 97.6637.8 NA
Monounsaturated NA 40.1617.6 NA
Polyunsaturated NA 13.666.9 NA
Saturated NA 28.7612.0 NA
Values are mean 6 standard deviation or absolute number (percentage); NA: Not available.
*Significant differences between the two populations p-value,0.05.
**Significant differences between the two populations, p-value,0.01.
***Significant differences between the two populations, p-value,0.001.
1This information was available for 1427 subjects.
2This information was available for 210 subjects.
doi:10.1371/journal.pone.0031853.t002
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completely disappeared after exclusion of subjects with type 2
diabetes.
Regarding the haplotype association analysis, the previously
associated haplotypes with type 2 diabetes were also significantly
associated with HOMA-IR expressed as a quantitative trait but as
it happened with the individual analysis, there was a weaker
association after removing those subjects under diabetic treatment
and there was no association after exclusion of all the type 2
diabetic subjects.
The individual SNP and haplotype association analyses with
HOMA-IR for all subjects, all except diabetics under treatment
and exclusively for non diabetic individuals are shown in Table 4.
The prevalence of type 2 diabetes according to genotypes of the
rs2197076 under dominant model in Hortega, Segovia and in the
pooled analysis is shown in Figure 2 as well as the HOMA-IR
values in the Segovia study.
Genetic and environment interaction
In Hortega population, the strength of association between
genotypes and haplotypes of the FABP1 and DM2 were slightly
higher in the group of low fat intake [OR 2.56, p-value 0.0056]
than that observed in the group of high fat intake [OR 2.04, p-
value 0.027]. No formal interaction among fat intake and
genotypes of the rs2197076 for the risk of type 2 diabetes was
found. Saturated or poly-unsaturated fat intake, expressed as a
quantitative trait or as a qualitative trait, did not interact with the
genotypes in the risk of type 2 diabetes. The individual SNP and
haplotype association analysis according to the groups of fat intake
are shown in Table 5.
Discussion
The data from the present study expand previous studies of
association of FABP genes in the risk of having type 2 diabetes and
insulin resistance. One single nucleotide polymorphism of the
FABP-1 gene, rs2197076 and one haplotype were associated with
an increased risk of type 2 diabetes even when adjusted for age, sex
and BMI. The replication analysis, not only for the individual SNP
but also for the haplotype in a population with a different
metabolic profile supports our initial findings. In this last
population, the SNP and the haplotype could also be related with
HOMA-IR. Carriers of the A allele of the rs2197076 of FABP1 or
those with the haplotype AT of the rs2197076 and rs2241883 had
significantly higher levels of HOMA-IR than those with the major
allele G of the rs2197076.
The evaluation of the total, saturated or poly-unsaturated fat
intake, as potential environmental factors, which could influence
the genetic association, was inconclusive. Although the level of
association was more evident in the low fat intake group, the
formal test for interaction was not significant.
The implication of the FABP genes on the risk of DM2 or insulin
resistance has been supported by experimental studies in animals
as well as in humans [22]. Liver fatty acid binding protein (FABP1)
is an abundant cytosolic lipid-binding protein that regulates lipid
transport and metabolism. Deletion of the FABP1 gene shows no
obvious phenotype in mice receiving a low fat chow diet, but leads
to decreased hepatic triglyceride accumulation in the prolonged
fasted state, which exposes mice to an increased fatty acid flux to
the liver. The function of the FABP1 gene may be regulated by
polymorphisms in coding regions, probably leading to modifica-
tions in hepatic triglycerides accumulation and hepatic insulin
resistance. Impairment of the function of this gene can lead to
several metabolic disturbances such as insulin resistance, non-
alcoholic esteatohepatitis and several components of the so-called
metabolic syndrome [23].
Among all the polymorphisms which have been tested for their
relationship with obesity and type 2 diabetes within the FABP1
gene, the functional mutation rs2241883 (p.Thr94Ala) has been the
most studied. According to our results while there was no
association with the p.Thr94Ala in our populations, haplotypes
containing the allele T (wild allele) were significantly associated
with the risk of type 2 diabetes in both populations and in the
pooled analysis. The p.Thr94Ala polymorphism induces an amino-
acid change that is located within the N-terminal region of the
protein which is a component of the fatty acid binding site and
therefore the binding capacity might be reduced in patients with
the 94Ala variant [24]. In the study carried out by Brouillette et al,
they found that carriers of the 94Ala allele had higher baseline
FFA, lower BMI and waist circumference than homozygotes
Thr94Thr [6]. In our associated haplotypes, the direction of the
association was driven by alleles of the rs2197076 and not by
alleles of the functional mutation. Our results suggest that the most
strongly associated SNP (rs2197076), because of its location in the
3 prime UTR site and its association with a potential functional
variant in one risk haplotype, could regulate the functional activity
of the protein individually or in haplotypes. It is likely that the A
allele of the rs2197076 might therefore reduce FABP1 gene
expression thereby contributing to enhance that situation of IR-
lipotoxicity, IR and DM2.
Type 2 diabetes and insulin resistance are intimately related and
therefore it is very difficult to separate one from the other. The
association with the HOMA-IR index values disappeared after the
exclusion of diabetic subjects what supports the association with
type 2 diabetes. We cannot be sure if the association with type 2
diabetes is mediated through insulin resistance or not. It is well-
known that both traits, insulin resistance and type 2 diabetes are
strongly influenced by genetics with an estimated heritability for
insulin resistance of around 60% and around 35–54% for the
plasma insulin levels in familial and twin studies [25]. Type 2
diabetes patients usually have lipid abnormalities with high levels
of plasma triglycerides and free fatty acids eventually leading to
Figure 1. Linkage disequilibrium of the associated region of
FABP1 using the R-square color scheme.
doi:10.1371/journal.pone.0031853.g001
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increased FFA flow from the peripheral tissues (muscle, liver)
causing lipotoxicity and hence IR.
We did not find an association of FABP1 variants with other
diabetes related traits such as hypertriglyceridemia, hypertension,
low HDL or high LDL cholesterol. Only there was a trend for the
association with hypertriglyceridemia and hypercholesterolemia
LDL but only in Segovia population and only with the qualitative
trait but not with the quantitative trait. The same occurred for
several variants of the intestinal FABP gene which were close to the
significance after Bonferroni correction with hypertriglyceridemia
but only in Segovia and only with the qualitative trait.
The main limitations of the present study are the lack of FFA
levels in our populations and the absence of functional studies of
the gene variants. Other limitation was related to the low
genotyping call rate observed in many of the samples (around
19% in Hortega and 35% in Segovia). We decided to exclude
those samples in an attempt to not compromise the results. We
believe that the problems with those subjects with very low call
rate were due to DNA problems although the amount of DNA and
the ratio 260/280 were within the optimal range. After the
exclusion of these problematic samples the genotyping call rate
was very high as it has to be because of the high accuracy of the
SNPlex platform [26]. The major strength is that we were able to
replicate the results in an independent Spanish population. Since
the two populations belong to the same geographical region and
that region has a low immigration rate, we do not expect bias in
our results due to population stratification. For this reason as the
genetic background was expected to be the same in both studies
we decided the pooled strategy over other strategies such as meta-
analysis in order to increase our sample size what is crucial to
detect variants of low risk. The different metabolic profile observed
between populations could be related with the different sampling
methodology but especially with the different characteristics of the
target populations. Individuals of Segovia population were selected
in a primary care environment and the majority belonged to rural
areas. They were also significantly younger than those from the
Hortega study. The individuals from the latter study were
recruited in the area covered by a tertiary hospital and majority
of them lived in urban areas. This population was also even
regarding to gender distribution compared with Segovia popula-
tion which included mostly females. Because of the potential
influence of the population to which each individual belongs, we
also adjusted the analysis by this factor, and the association of the
polymorphism rs2197076 and type 2 diabetes remained highly
significant [OR 1.83 (1.38–2.43), Bonferroni p-value 0.0003 for
the additive model and OR 2.11 (1.51–2.95), Bonferroni p-value
0.00013 for the dominant model] .
Also important is the inclusion of fat intake as a possible factor
of interaction between the gene variants and metabolic traits.
In summary, our study supports the role of the liver FABP in the
development of type 2 diabetes and insulin resistance in
representative samples of Spanish general population. Functional
Figure 2. Prevalence of type 2 diabetes and HOMA-IR values according to genotypes of the rs2197076. [Bottom: Prevalence of DM2 for
genotypes of the rs2197076 under dominant model. Inside the bars are shown the number of individuals for each genotype; Top: Mean of HOMA-IR
for genotypes of the rs2197076 in Segovia population under dominant model. Inside the circles are the number of individuals for each genotype.
*Chi-square test for the comparison of type 2 diabetes prevalence between genotypes].
doi:10.1371/journal.pone.0031853.g002
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studies may clarify in the future if the liver FABP may or may not
be a potential target for treatment of type 2 diabetes and insulin
resistance.
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